BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma.

Autor: Requirand G; CHU Montpellier, Department of Biological Hematology, Montpellier, France.; IGH, CNRS, University of Montpellier, Montpellier, France., Robert N; CHU Montpellier, Department of Biological Hematology, Montpellier, France.; IGH, CNRS, University of Montpellier, Montpellier, France., Boireau S; CHU Montpellier, Department of Biological Hematology, Montpellier, France.; IGH, CNRS, University of Montpellier, Montpellier, France., Vincent L; CHU Montpellier, Department of Clinical Hematology, Montpellier, France., Seckinger A; Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany.; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany., Bouhya S; CHU Montpellier, Department of Clinical Hematology, Montpellier, France., Ceballos P; CHU Montpellier, Department of Clinical Hematology, Montpellier, France., Cartron G; CHU Montpellier, Department of Clinical Hematology, Montpellier, France.; University of Montpellier, UFR de Médecine, Montpellier, France., Hose D; Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany.; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany., Klein B; CHU Montpellier, Department of Biological Hematology, Montpellier, France.; IGH, CNRS, University of Montpellier, Montpellier, France.; University of Montpellier, UFR de Médecine, Montpellier, France., Moreaux J; CHU Montpellier, Department of Biological Hematology, Montpellier, France.; IGH, CNRS, University of Montpellier, Montpellier, France.; University of Montpellier, UFR de Médecine, Montpellier, France.; UMR CNRS 5235, University of Montpellier, Montpellier, France.
Jazyk: angličtina
Zdroj: Cytometry. Part B, Clinical cytometry [Cytometry B Clin Cytom] 2019 May; Vol. 96 (3), pp. 209-214. Date of Electronic Publication: 2018 Nov 12.
DOI: 10.1002/cyto.b.21730
Abstrakt: Background: Mutiple myeloma (MM) is a neoplasia characterized by the accumulation of malignant plasma cells (PC) in the bone marrow. Although proliferation markers have been studied in MM, none of the current staging systems include them. Moreover, approaches used to analyze proliferation do not separate MM cells (MMCs) from normal PC.
Methods: In this study, we combined multiparameter flow cytometry and BrdU incorporation or Ki67 staining to analyze MM cell proliferation in 44 monoclonal gammopathy of undetermined significance (MGUS), 153 newly diagnosed MM patients and 69 MM patients at relapse. The prognostic value of proliferation assessment was analyzed in 60 newly diagnosed patients treated with high-dose chemotherapy supported by autologous hematopoietic stem cell transplantation.
Results: The median number of proliferating malignant PC significantly increases during MM disease progression. MM patients with a percentage of proliferating MMCs greater than 1.42% using BrdU/DAPI or greater than 1.1% using ki67/DAPI, are associated with a significantly shorter event free survival compared with patients with a lower percentage of proliferating MMCs.
Conclusions: Combination of flow cytometry with BrdU or ki67/DAPI staining could become a standard for the determination of MM cell proliferation. Furthermore, in the context of new effective myeloma treatment options, assessment of MM cell proliferation may be valuable, in clinical trials, to identify novel agents that could significantly affect the small proliferative compartment of MM cells. © 2018 International Clinical Cytometry Society.
(© 2018 International Clinical Cytometry Society.)
Databáze: MEDLINE
Externí odkaz: